



**Press release**  
October 17, 2014  
Gothenburg

## Conference call interim report

**Invitation to attend XVIVO Perfusion's conference call regarding presentation of the interim report for the period January - September, 2014. The presentation will be held in English.**

Time: Friday, October 24, 2014 at 2.00 p.m. CET

Registration can preferably be done in advance under the following link:  
<https://engage.vevent.com/rt/xvivoperfusion~2014-10-24>

or shortly before time of the conference starts on:

Sweden dial in number: 08 506 921 80

International dial in number: +44 (0) 2071 928 000

Conference name: XVIVO Perfusion, conference ID: 19023328

Participants from XVIVO Perfusion:

Magnus Nilsson, CEO

Christoffer Rosenblad, CFO

The press release for XVIVO Perfusion's interim report for the period January – September, 2014 will be released before the conference call October 24, 2014.

Before the conference call, slides will be available at the company web page, [www.xvivoperfusion.com/corporate/](http://www.xvivoperfusion.com/corporate/).

October 17, 2014

Gothenburg

XVIVO Perfusion AB (publ)

For further information, please contact

Christoffer Rosenblad, CFO, +46 31 788 21 59, [christoffer.rosenblad@xvivoperfusion.com](mailto:christoffer.rosenblad@xvivoperfusion.com)

---

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website [www.xvivoperfusion.com](http://www.xvivoperfusion.com). The Certified Adviser is Redeye, [www.redeye.se](http://www.redeye.se).

---

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.

Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.

E-mail: [info@xvivoperfusion.com](mailto:info@xvivoperfusion.com). Website: [www.xvivoperfusion.com](http://www.xvivoperfusion.com)

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.